Skip to main content
. 2016 Jun 14;11(6):e0157130. doi: 10.1371/journal.pone.0157130

Table 3. Spearman correlation analysis of Met content, pMet content, Gleason score and clinical T and N stage for patient tumor samples1 in the prostate adenocarcinoma (PRAD) TCGA Provisional dataset.

Parameter Met2 vs Gleason3 pMet2 vs Gleason3 Met vs T stage4 pMet vs T stage4 Met vs N stage5 pMet vs N stage5
Number of XY Pairs 352 352 348 348 309 309
Spearman r -0.1458 0.03617 -0.1503 0.07766 -0.1460 0.08555
95% confidence interval -0.2495 to -0.03875 -0.07173 to 0.1432 -0.2544 to -0.04278 -0.03084 to 0.1843 -0.2565 to -0.03163 -0.02962 to 0.1985
P value (two-tailed) 0.0061 0.4988 0.0050 0.1483 0.0102 0.1335

1All tissue samples in the PRAD TCGA RPPA Provisional cohort (n = 352) are primary prostate tumor samples

2Content scores determined by RPPA analysis

3N values for each Gleason score subgroup, from 6 to 10, are shown in Fig 2B

4N values for each T stage subgroup, from T2a to T4, are shown in Fig 2A; stage data for 4 cases was unavailable

5The N0 subgroup contained 246 cases, the N1 subgroup, 62 cases